Cure My Disease

Don't miss your cure!

 Log in / Sign up

Dialysis showdown: which method protects heart and bones best?

NCT ID NCT07686978

Knowledge-focused Sponsor: Gazi University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study looks at how different types of dialysis affect heart health, bone metabolism, inflammation, and quality of life in people with end-stage kidney disease. Researchers will compare patients on hemodialysis, continuous ambulatory peritoneal dialysis, and automated peritoneal dialysis, as well as healthy volunteers. No new treatments are given—participants continue their usual care while researchers measure blood markers, artery stiffness, body composition, and symptoms like itching and pain. The goal is to understand which dialysis method may be gentler on the body.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors choose the best dialysis method to reduce heart and bone complications in kidney disease patients.
What could go wrong
This is an observational study, not a treatment trial, so it cannot prove cause and effect. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult participants will be recruited from the Gazi University Faculty of Medicine nephrology outpatient clinic and dialysis units. The study population will include four cohorts: patients receiving maintenance hemodialysis, patients receiving continuous ambulatory peritoneal dialysis, patients receiving automated peritoneal dialysis, and healthy controls without known kidney disease. Dialysis patients must have been receiving regular dialysis treatment for at least 6 months. Healthy controls will have no known kidney disease, systemic inflammatory disease, or active malignancy.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 to 80 years. * For dialysis cohorts: diagnosis of end-stage kidney disease and receiving maintenance hemodialysis or peritoneal dialysis. * For dialysis cohorts: receiving regular hemodialysis, continuous ambulatory peritoneal dialysis, or automated peritoneal dialysis for at least 6 months. * For healthy controls: no known kidney disease, with estimated glomerular filtration rate greater than 90 mL/min/1.73 m². * For healthy controls: no known systemic inflammatory disease or active malignancy. * Able to comply with planned study procedures, including pulse wave velocity measurement, Body Composition Monitor assessment, questionnaires, and biomarker measurements. * Able and willing to provide written informed consent. Exclusion Criteria: * Inability to comply with study measurements or questionnaire assessments. * Refusal or inability to provide written informed consent. * Age younger than 18 years or older than 80 years. * Acute infection. * Recent major surgical intervention. * Active malignancy. * Terminal illness with limited life expectancy. * Mental, cognitive, physical, or clinical condition preventing participation in study procedures.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for End stage kidney disease (ESKD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease end stage renal failure sclerosteosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

End stage kidney disease (ESKD) Hemodialysis Peritoneal dialysis (PD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Gazi University Faculty of Medicine, Department of Nephrology

    Ankara, Ankara, 06500, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.